Septerna Inc (SEPN)

NASD · Healthcare · Biotechnology · USA

Septerna Inc is a small cap company (market value between $300 million and $2 billion) in the Biotechnology industry.

Septerna is a clinical-stage biotechnology company developing oral small molecule drugs targeting G protein-coupled receptors using its proprietary Native Complex Platform. The company has a pipeline of product candidates in endocrinology, immunology and inflammation, and metabolic diseases.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Septerna Inc stock.

Our verdict on SEPN

Not valued: We cannot value this company yet.

We do not publish a value for this company: its filings cover three fiscal years and projecting growth needs four in a row.

ETFs with the most weight in SEPN

17 more funds hold it; the full list is part of the paid plan.

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Cheaper than SEPN in Biotechnology

129 more in this industry show a wider margin of safety.

Is SEPN undervalued or overvalued?

We do not publish a verdict on SEPN yet. A discounted cash flow projects five years of revenue, so it needs this company’s own growth history: four consecutive fiscal years of accounts, which give three year-on-year growth rates. Its filings on our archive cover three fiscal years so far; the next annual report should close the gap. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.

What is the intrinsic value of SEPN?

We do not publish one (as of the 2026-11-17 close). A discounted cash flow projects five years of revenue, so it needs this company’s own growth history: four consecutive fiscal years of accounts, which give three year-on-year growth rates. Its filings on our archive cover three fiscal years so far; the next annual report should close the gap. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.